Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Posts Meager Q3 Revenue Growth as Profit Turns to Loss

NEW YORK (GenomeWeb News) — Affymetrix today reported that revenue for the third quarter increased around 1 percent as last year's profit swung to a loss.
 
Total receipts for the three months ended Sept. 30 inched up to $84.6 million from $83.4 million year over year
 
Affy said $59.8 million in revenue during the period came from GeneChip sales while about $10.1 million was made on reagent revenue and $7.7 million from its genotyping services.  
 
Affy spent $21.6 million on research and development in the quarter, an increase of about 9 percent over last year.
 
Affy said a $9.4-million profit last year turned into a $14.2-million loss this year. Affy blamed the higher losses primarily on the reduced price of the company’s 500K Mapping Array. The company said it lowered the price in July “ahead of the planned shipments of a single-array 500K in the fourth quarter.”  
 
The company said it holds $66.5 million in cash and cash equivalents and $179 million in available-for-sale short-term securities.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.